Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

1 article from the last 30 days matching "oral medication"

ResearchRSS3 days ago

SMA patients stick with Evrysdi for years, real-world study finds

A study in Spain found that people with spinal muscular atrophy (SMA) who take Evrysdi, an oral medication, stick with the treatment long-term. All patients in the study continued taking the drug, with some staying on it for over three years. This shows the medication is well-tolerated and patients find it easy to keep using.

WHY IT MATTERSIf you or your child has SMA and are considering Evrysdi, this real-world evidence shows that patients successfully stay on the treatment for years, suggesting it's a practical long-term option with good tolerability.
💬 Ask your doctorspinal muscular atrophy

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases